Literature DB >> 17161166

Why cancer staging? FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

J L Benedet, S Pecorelli.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17161166     DOI： 10.1016/S0020-7292(06)60026-X

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN： 0020-7292            Impact factor:   3.561


× No keyword cloud information.
  3 in total

1.  Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.

Authors:  Joyce N Barlin; Robert A Soslow; Megan Lutz; Qin C Zhou; Caryn M St Clair; Mario M Leitao; Alexia Iasonos; Martee L Hensley; Richard R Barakat; Xavier Matias-Guiu; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

2.  Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.

Authors:  Fake Li; Ruxiu Tie; Kai Chang; Feng Wang; Shaoli Deng; Weiping Lu; Lili Yu; Ming Chen
Journal:  BMC Cancer       Date:  2012-06-19       Impact factor: 4.430

3.  Clinical implication of subcategorizing T2 category into T2a and T2b in TNM staging of breast cancer.

Authors:  Jiwoong Jung; Young Jin Suh; Byung Kyun Ko; Eun Sook Lee; Eun-Kyu Kim; Nam Sun Paik; Kyung Do Byun; Ki-Tae Hwang
Journal:  Cancer Med       Date:  2018-10-12       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.